Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRT19 interacting long noncoding RNA in hepatocellular carcinoma (KILH)
- Target
- KILH
- Molecular classification
- Long noncoding RNA (lncRNA), Other
01
Overview
KRT19 interacting long noncoding RNA in hepatocellular carcinoma (KILH) is a long noncoding RNA predominantly expressed in KRT19-positive hepatocellular carcinoma cells. KILH binds specifically to KRT19 protein, inhibits its phosphorylation at the Ser35 residue, and enhances KRT19’s interaction with β-catenin, facilitating the nuclear translocation and activation of the Notch1 signaling pathway. Functionally, KILH promotes HCC cell proliferation and metastasis and is upregulated in HCC tissues compared to non-tumor liver tissues, making it a strong candidate for therapeutic targeting and prognostic biomarker in liver cancer. Knockdown of KILH suppresses HCC tumor growth and metastasis in both in vitro and in vivo models.
- Other names
- Linc-KILHlinc-KILHlnc-GCLC-1ENST00000504928.1
02
Mechanism of action
Drugs targeting KILH would theoretically act by inhibiting its expression or disrupting its interaction with KRT19, thereby reducing Notch1 signaling and decreasing cell proliferation/metastasis
03
Biological functions
Regulation of protein phosphorylationRegulation of KRT19 subcellular localizationPromotion of Notch1 signalingEnhancement of cell proliferationEnhancement of cell metastasis
04
Disease associations
Cancerspecifically hepatocellular carcinoma (HCC)
05
Safety considerations
Potential off-target effects due to KILH’s role in interacting with multiple proteinsunknown long-term physiological impact of KILH inhibitionpossible need to target only KRT19-positive HCC to avoid effects in non-tumoral hepatic tissues
06
Biomarkers
KILH itself is upregulated in HCC tissues and correlates with tumor progression and poor prognosisKRT19, Notch1, and β-catenin are associated downstream markers
Beyond the preview
Go deeper on KRT19 interacting long noncoding RNA in hepatocellular carcinoma (KILH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRT19 interacting long noncoding RNA in hepatocellular carcinoma (KILH).